The 2026 in-cosmetics Korea, Asia’s premier personal care ingredients exhibition, is set to grandly open in Seoul. Zhiyuan and Xinzhiyuan Biotechnology will be showcasing a wide range of innovative water-soluble modified raw materials at Booth C-G31. We sincerely invite industry peers to visit us for discussions and collaboration opportunities!
Zhiyuan Biotechnology boasts a fully integrated industrial chain covering R&D, experimentation, testing, and large-scale production – from lab-scale development to hundred-ton-level commercial manufacturing. We offer customized raw material development services to meet specific client needs. With rigorous quality control throughout the entire process, we ensure consistent product quality and batch-to-batch stability. We continue to deepen our expertise in cyclodextrin and chitosan application technologies, delivering comprehensive one-stop raw material solutions tailored to your requirements.
Exhibition Information
Event The 11th in-cosmetics Korea
Date July 1 – 3, 2026
Venue COEX Convention Center, Seoul, South Korea
Exhibitors Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. & New Source Chemical
Booth No. C-G31
Tel +86-543-2616568 / +86-531-61303628
Email info@cydextrin.com
Official Websites www.cydextrins.com , www.newsourcechem.com
Products on Display:
✅ High-content water-soluble active ingredients: Water-soluble Salicylic Acid, Water-soluble Azelaic Acid
✅ Mainstream cyclodextrin raw materials: Hydroxypropyl Cyclodextrin, Methyl-β-Cyclodextrin, Hyperbranched Cyclodextrin
✅ Chitosan-based skincare ingredients: Hydroxypropyl Chitosan, Carboxymethyl Chitosan
✅ Custom cyclodextrin inclusion complexes: Water-soluble functional inclusion complexes of Ferulic Acid, Resveratrol, and more
Our professional team will be on-site at Booth C-G31 to provide technical support and business consultations. We warmly welcome colleagues and partners from all sectors to visit, exchange ideas, and explore cooperation.
Committed to innovation and quality, we continue to expand our applications across cosmetics, pharmaceuticals, food, and beyond – helping our customers develop superior products. We look forward to meeting you at this grand event in Seoul this July – together, we grow and win!
The 24th World Pharmaceutical Ingredients China Exhibition (CPHI & PMEC China 2026) is scheduled to be grandly inaugurated from June 16 to 18, 2026, at the Shanghai New International Expo Center. As a high-tech enterprise integrating research and development, production, and application, Shandong Binzhou Zhiyuan Biotechnology has long been dedicated to the fields of cyclodextrin derivatives, cyclodextrin inclusion complexes, and chitosan derivatives. We sincerely invite you to our booth E6B59, where we will centrally showcase our cyclodextrin and chitosan product lines, core technologies, and tailored solutions, and collaborate with upstream and downstream partners in the pharmaceutical industry chain to explore emerging opportunities in the sector.
Exhibition Details
Exhibition Name: CPHI & PMEC China 2026
Exhibition Period: June 16–18, 2026
Venue: Shanghai New International Expo Center
Booth Number: E6B59
Exhibiting Entity: Shandong Binzhou Zhiyuan Biotechnology Co., Ltd.
Appointment for Consultation: 86543-2616568 info@cydextrin.com
Throughout the exhibition, our professional technical and business teams will be stationed at Booth E6B59 to provide one-on-one technical consultation, solution alignment, and business negotiation services. We anticipate in-depth exchanges with both new and existing partners, jointly exploring the cutting-edge applications of cyclodextrins and chitosan in pharmaceuticals, cosmetics, and other domains, and striving collaboratively to achieve mutual success in the future!
From April 14 to 16, In-Cosmetics Global 2026 will open at the Paris Expo Porte de Versailles. Zhiyuan Bio-tech from Binzhou, Shandong, will present a range of core innovative beauty ingredients (Booth 2D40), inviting global industry peers to explore trends and discuss collaboration.
Core Exhibited Products, Driving Efficacy Innovation, Addressing Industry Pain Points
Zhiyuan Bio-tech will showcase its star ingredients, including cyclodextrin, chitosan, water-soluble salicylic acid, and water-soluble azelaic acid. Leveraging its core cyclodextrin inclusion technology, these products offer advantages such as moisturizing, repairing, active ingredient solubilization, and controlled release, meeting the formulation needs of high-end skincare and efficacy-focused cosmetics while solving key application challenges in the industry.
Deep Technological Expertise, Connecting Global Markets, Empowering Industry Advancement
Guided by technological innovation, Zhiyuan Bio leverages its three-pronged advantage of “technology, compliance, and customization” to export its products to markets including Europe, the Americas, Japan, and South Kore. The company’s participation in this exhibition aims to connect with global brands and R&D teams, share innovative achievements, expand its international presence, and provide safe and efficient raw material solutions for the global beauty industry.
Visiting Our Booth, Charting the Future of Beauty, Starting a New Chapter of Cooperation
Zhiyuan Bio will be at Booth 2D40. We sincerely invite industry professionals and partners to visit us for discussions. On-site, we provide one-stop services including raw material consultation, formulation solutions, and customized development, as we join hands to capture new opportunities in the beauty industry.
Contact us: info@cydextrin.com // +86 543 2616568
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd., a leading innovator in cyclodextrin technology and applications, is pleased to announce its participation in the upcoming China International Cosmetics and Personal Care Ingredients Exhibition (PCHi 2026). The event will take place from March 18 to 20, 2026, at the Hangzhou Convention and Exhibition Center.
Under the theme “Focusing on Cyclodextrin Encapsulation, Providing Customized Services,” Zhiyuan Biotechnology will welcome visitors at Booth 3C55 in Hall 3. The company will present its latest advancements in cyclodextrin technology, demonstrating how its innovative solutions address key challenges in cosmetic and personal care formulations. By offering efficient, safe, and high-performance raw material solutions, Zhiyuan aims to empower global customers with cutting-edge ingredients that enhance product efficacy and consumer experience.
Key Product Highlights at PCHi 2026:
65% Water-Soluble Azelaic Acid:
This innovative product significantly improves the solubility of azelaic acid in water while maintaining its full efficacy. It enables controlled slow release to prolong the active effect and effectively regulates local concentration, resulting in reduced skin irritation.
40% Water-Soluble Salicylic Acid:
Designed to enhance the solubility of salicylic acid in aqueous systems, this technology regulates the release rate and controls the local concentration on the skin surface. It ensures effective concentration levels while minimizing potential irritation.
Hyperbranched Cyclodextrin:
Offering highly effective encapsulation and protection for multiple active ingredients, hyperbranched cyclodextrin improves formulation stability and enhances hydrophilicity for better dispersion across various dosage forms. It enables precise regulation through sustained release and targeted delivery capabilities.
Hydroxypropyl Cyclodextrin:
This versatile derivative improves the solubility of poorly soluble raw materials, reduces irritation caused by organic molecules, and enhances overall formulation stability. It also regulates the release rate of active ingredients while effectively masking undesirable odors. In addition to these cyclodextrin-based innovations, Zhiyuan Biotechnology will showcase hydroxypropyl deacetylated chitosan and other cyclodextrin derivatives. These products demonstrate significant advantages in regulating local concentration, reducing irritation, improving formulation stability, and achieving sustained and controlled release.
Exhibition Details: Dates: March 18–20, 2026
Venue: Hangzhou Convention and Exhibition Center (Nanyang Street, Xiaoshan District, Hangzhou City, Zhejiang Province)
Booth Number: 3C55
BINZHOU, China – March 2026 –
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd., a dedicated specialist in the field of functional excipients, is proud to announce a significant breakthrough in its corporate development. The company has successfully obtained the Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP) for its Betadex Sulfobutyl Ether Sodium product. This prestigious certification marks a new chapter for the company, affirming its technical expertise and opening doors to international markets.
Since its inception, Binzhou Zhiyuan Biotechnology has recognized the immense potential of cyclodextrin. As a functional excipient characterized by its unique cyclic molecular structure, cyclodextrin plays a vital role across numerous sectors, including pharmaceuticals, food, daily chemicals, and agriculture, owing to its exceptional solubilizing, encapsulating, and stabilizing properties. Committing itself to this niche market, the company has evolved from small-batch trial productions to operating a state-of-the-art production facility equipped with advanced machinery and a comprehensive quality control system. This journey of growth has been fueled by the ingenuity of its R&D team and the dedication of its production staff.
For sixteen years, the company has maintained a meticulous focus on process research and development. Significant human, material, and financial resources have been consistently invested in process optimization and technological innovation. The R&D team has conducted in-depth studies on the molecular structure and reaction mechanisms of cyclodextrin to continuously refine production parameters. Every step of the process—from raw material selection and fermentation preparation to separation, purification, and final product testing—has been repeatedly optimized. Through a strategy combining independent research with technology introduction, Binzhou Zhiyuan has successfully overcome numerous technical challenges. These efforts have resulted in significantly improved product purity and yield, reduced production costs, and a minimized environmental footprint.
Betadex Sulfobutyl Ether Sodium (SBECD) is a novel solubilizer and stabilizer widely used in injectable formulations of poorly soluble drugs, including critical medications such as remdesivir, voriconazole, and aripiprazole. The acquisition of the CEP certificate for this key product is not only an authoritative endorsement of Binzhou Zhiyuan’s R&D capabilities and stringent production quality systems but also establishes a new trajectory for the company’s leapfrog development in the global pharmaceutical excipient market. This achievement positions Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. for continued growth and innovation as it strives to provide high-quality solutions to its customers worldwide.
The CPHI & PMEC Pharmaceutical Industry Exhibition (Shenzhen) will grandly open from September 1 to 3, 2025, at the Shenzhen Convention and Exhibition Center (Futian). The CPHI Shenzhen exhibition will fully stimulate the internal drive and innovative vitality of pharmaceutical enterprises, inject strong development momentum into the global pharmaceutical value chain, and jointly explore new growth opportunities for the pharmaceutical industry in the Greater Bay Area and Asia.
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd., along with its subsidiary Jinan Xinzhiyuan Biotechnology Co., Ltd., will appear at the CPHI & PMEC Pharmaceutical Industry Exhibition (Shenzhen) held at the Shenzhen Convention and Exhibition Center (Futian) from September 1 to 3, 2025, at Booth 9i28. They will prominently launch new products: “Hydroxypropyl Chitosan” and “Carboxymethyl Chitosan.” This participation aims to deepen industry collaboration and promote the innovative application of cyclodextrin derivatives and chitosan derivatives in fields such as pharmaceuticals and daily chemicals.
Zhiyuan Biotechnology looks forward to exchanging and collaborating with more industry peers to jointly advance innovation and development in the pharmaceutical industry. We believe that through this exhibition, Zhiyuan Biotechnology will be able to establish connections with more industry colleagues and collectively drive the prosperous development of the pharmaceutical sector. At the same time, we also look forward to meeting friends at the exhibition to discuss cooperation and create a brilliant future together!
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd focuses on pharmaceutical&cosmetic raw materials. Equipped with an international R&D team and a stringent quality system. We will participate in In-cosmetics Korea 2025.
Exhibitor: Shandong Binzhou Zhiyuan Biotechnology Co., Ltd
Booth No.: B45
Name: In cosmetics Korea 2025
Time: 2-4 July , 2025
Location: COEX Convention Center, Seoul, Korea
Our exhibited products
Hydroxypropyl Chitosan、Hydroxypropyl betadex 、Methyl beta cyclodextrin、40% Water-soluble Salicylic acid、60% Water-soluble Azelaic acid, etc.
We sincerely invite you to visit our Boss No.: B45 to to explore cooperation opportunities
Contact:
info@cydextrin.com
Phone:86-543-2616568 86-531-61303628
Website: www.cydextrins.com
Highly soluble cocrystals can be used to improve bioavailability of a poorly soluble drug, through generating supersaturation, when absorption is limited by drug dissolution. Dihydromyricetin (DMY) is a biopharmaceutics classification system (BCS) IV drug, exhibiting dissolution limited absorption.
Two novel soluble cocrystals of (±)DMY with caffeine and urea, and their physicochemical properties were evaluated for suitability in formulation development. Although having a much higher solubility than (±)DMY, both cocrystals undergo rapid precipitation during dissolution and form the poorly soluble (±)DMY dihydrate in aqueous media. This negates the potential advantage offered by the high solubility of the two cocrystals in enhancing the dissolution rate and in vivo bioavailability. To solve this problem, we have systematically evaluated suitable crystallization inhibitors to maintain the supersaturation generated by cocrystal dissolution over a prolonged period of time. At 37 °C, an approximately 5-fold enhancement in oral bioavailability of (±)DMY was achieved when both cocrystals were dosed with 2.0 mg/mL polyvinylpyrrolidone K30 solution than (±)DMY dihydrate suspended in 0.5 mg/mL carboxymethylcellulose sodium solution. The study demonstrates that the use of a highly soluble cocrystal along with an appropriate crystallization inhibitor is a potentially effective formulation strategy for improving oral bioavailability of poorly soluble BCS IV drugs.
Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT). In addition, letermovir has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan. This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.
Hydroxypropyl beta Cyclodextrin is an ideal solubilizer and excipient for injection.
1.Solubilization and solubilization, dissolve insoluble drugs, improve the solubility of Active ingredient of oily drugs, target drug delivery and protect the effectiveness of drug ingredients.
2.Improve the bioavailability of drugs to increase their efficacy or reduce their dosage.
3.Adjust or control the release rate of drugs to reduce drug toxicity and side effects.
4.Cover up bad odors.
Enterovirus D68 (EV-D68) is a member of the Picornavirus family and a causative agent of respiratory diseases in children. The incidence of EV-D68 infection has increased worldwide in recent years. Thus far, there are no approved antiviral agents or vaccines for EV-D68. In the recently published study of Jiang et al. (Jilin University, China) show that 2,6-Di-O-methyl-Beta-cyclodextrin (methyl-β-cyclodextrin), a common drug that disrupts lipid rafts, specifically inhibits EV-D68 infection without producing significant cytotoxicity at virucidal concentrations. The addition of exogenous cholesterol attenuated the anti-EV-D68 activity of 2,6-Di-O-methyl-Beta-cyclodextrin. 2,6-Di-O-methyl-Beta-cyclodextrin treatment had a weak influence on the attachment of viral particles to the cell membrane (RD cells and HeLa cells) but significantly inhibited EV-D68 entry into host cells. It was demonstrated that EV-D68 facilitated the translocation of the viral receptor protein ICAM-5 to membrane rafts in infected cells. The colocalization of viral particles with ICAM-5 in lipid rafts was thoroughly abolished in cells after treatment with 2,6-Di-O-methyl-Beta-cyclodextrin. It was also shown that 2,6-Di-O-methyl-Beta-cyclodextrin inhibited the replication of isolated circulating EV-D68 strains. The anti-EV-D68 activity of 2,6-Di-O-methyl-Beta-cyclodextrin is mainly mediated by modulating host cell resistance to EV-D68 entry but not the direct binding of virions.
In summary, the results demonstrate that 2,6-Di-O-methyl-Beta-cyclodextrin suppresses EV-D68 replication by perturbing the accumulation of virus particles and ICAM-5 in lipid rafts.
2,6-Di-O-methyl-Beta-cyclodextrin
